Potential Risks and Considerations While BPC-157 shows enormous promise for gut healing, its important to understand the potential risksespecially since its not an FDA-approved treatment and lacks large-scale human trials
The trial program has evolved from glycemic-safety and outcomes studies in T2D (the LEADER, SUSTAIN-6, REWIND, EXSCEL, and PIONEER 6 era [10][13], [19]), to outcomes trials in expanded populations including obesity without diabetes (SELECT [3]), HFpEF with obesity (SUMMIT [5], with a companion semaglutide program in STEP-HFpEF [20], [21]), CKD (FLOW [22]), and an active-comparator setting (SURPASS-CVOT [6])
Thats coming to an end: The FDA declared the tirzepatide shortage over in December and did the same for the semaglutide shortage in February
But if you report any other E/M code on the same day of service, and properly append modifier 25 Significant, separately identifiable evaluation and management service by the same physician or other qualified health care professional on the same day of the procedure or other service to indicate a significant, separately identifiable E/M service was provided, the claim may be paid
